Главная страницаLBank Stocks
Adagene Inc
Adagene Inc

Adagene Inc (ADAG)

24HВысокий$1.9524HНизкий$1.48
$1.79
+0.21%

Последнее обновление: 2026-11-19 10:09:59

Симуляция графика K-линий, фактические данные указаны на торговой странице

Ключевые данные

Открытие вчера
$1.48
Пред. закрытие
$1.79
Вчерашний диапазон
$1.48 - $1.95
Диапазон 52 нед.
$1.27 - $4.85
Объем торговли
764.449K
МС
$99.372M
P/E
--
EPS
$-0.37

Обзор компании

NASDAQ

Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.

СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартираBUILDING C14, SUZHOU, CHINA, 215123
СтранаUSA
Дата листинга2021-02-09
Конец финансового года2026-06-30
Акции в обращении67.143M
Код CIK1818838

Финансовые показатели

Индикатор2026-06-302026-03-312025-06-302024-12-31
Доход$1.623M$7.693M--$103.204K
Операционные расходы$256.457K$282.32K$300.326K$926.248K
Чистая прибыль-$16.413M-$4.144M-$13.51M-$24.918M
Чистая рентабельность-1011.1%-53.9%---24144.7%
Прибыль на акцию--------
EBITDA-$16.365M-$5.484M-$15.426M-$22.703M
Эффективная налоговая ставка0.4%6.7%-0.0%0.1%

Часто задаваемые вопросы

Aditxt, Inc. (TICKER: ADAG) operates in the biotechnology sector, specializing in developing and commercializing immune monitoring and modulation technology. Its core focus is on enhancing immune system control, which includes applications in autoimmune diseases, organ transplantation, and immunotherapies.
ADAG's revenue model is primarily driven by the commercialization of its proprietary immune-monitoring platform and partnerships with healthcare providers, research institutions, and pharmaceutical companies. Licensing deals and collaborations for therapeutic applications represent potential revenue avenues for the company.
ADAG distinguishes itself through its patented immune modulation and monitoring technology, focusing on addressing immune-related conditions such as autoimmune diseases and organ transplant rejection. This approach provides a unique position compared to other general biotechnology firms primarily focused on drug manufacturing.
Key risks for ADAG investors include its reliance on early-stage biotechnology development, potential delays in product commercialization, regulatory hurdles, and competition from established biotech companies. Financial sustainability and funding requirements are also critical factors to consider in this growing sector.
Currently, ADAG does not pay dividends to shareholders. Biotechnology companies like ADAG often reinvest earnings into research and development to advance their proprietary technology and expand their market reach, which remains a priority over distributing profits to shareholders.
ADAG has significant growth opportunities in the rapidly expanding fields of immune health, personalized medicine, and organ transplantation. Its focus on innovative immune modulation technology could position it as an attractive partner for healthcare providers and pharmaceutical companies seeking advanced solutions.
ADAG's valuation reflects its position as a developing biotech company with early-stage revenue potential. Investors often compare such companies based on their proprietary technology, market potential, and investment in research relative to competitors’ market capitalization and financial health.
ADAG faces challenges related to demonstrating clinical efficacy, securing regulatory approvals, and establishing market adoption of its immune modulation technology. Additionally, the company needs funding to sustain long-term R&D initiatives while competing with established biotechnology firms in similar niches.
Предупреждение о рисках
  1. 1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
  2. 2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
  3. 3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.